NCT03255018View on ClinicalTrials.gov

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

October 22, 2022

Study Completion Date

June 29, 2023

Conditions
Non-Hodgkin LymphomaLymphomaDiffuse Large B-Cell LymphomaGray-zone LymphomaPrimary Central Nervous System Lymphoma
Interventions
BIOLOGICAL

Pembrolizumab

Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03255018 - Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | Biotech Hunter | Biotech Hunter